Could a probiotic supplement help reverse fatty liver?
NCT ID NCT06352697
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether a daily capsule containing fragments of a probiotic bacterium (L. rhamnosus) can reduce liver fat and improve blood markers in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants take either the supplement or a placebo for three months, with follow-up for another three months. The goal is to see if this postbiotic approach safely lowers liver fat and inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Probiotic lysate (postbiotic and metabiotic) from L. rhamnosus
What this could lead to
If effective, this supplement could offer a simple, non-drug way to reduce liver fat and inflammation in people with fatty liver disease.
What could go wrong
This is a small, early-stage trial with only 50 participants, so results may not apply broadly. The supplement may not significantly improve liver health, and long-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC STEATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bogomolets National Medical University
Kyiv, 01601, Ukraine
-
Center for Innovative Medical Technologies of the National Academy of Sciences of Ukraine
Kyiv, 02000, Ukraine
-
Danylo Halytsky Lviv National Medical University
Lviv, 79010, Ukraine
-
Kyiv City Clinical Endocrinology Center
Kyiv, 01601, Ukraine
-
Taras Shevchenko National University of Kyiv
Kyiv, 01601, Ukraine